Petroff D, Blank V, Newsome PN, et al. - Given that controlled attenuation parameter (CAP) is a non-invasive hepatic steatosis assessment tool that has become available for obese patients (FibroScan XL probe), but no consensus on cutoffs and their diagnostic output has been reached, researchers sought to evaluate diagnostic properties and identify relevant covariates with use of an individual patient data meta-analysis. PubMed and Web of Science were searched for studies published from database inception until April 30, 2019. Sixteen studies reported histology-controlled CAP including the XL probe, and individual data from 13 papers and 2,346 patients were involved. CAP cutoffs differed by cause, and in patients with viral hepatitis, significant steatosis may be effectively identified. CAP can not accurately grade steatosis in NAFLD patients, but it is important to research its importance in a NAFLD screening setting, preferably with methods outside the traditional histological reference standard.